Medicare and IBD Biologics: Part B vs Part D

Two people with the same diagnosis, on the same drug class, can get bills that look nothing alike under Medicare. The reason usually has less to do with the disease than with how the medication enters the body. Medicare sorts drugs into benefit categories, and for inflammatory bowel disease (IBD) therapies the dividing line falls between medications infused in a clinic and medications you inject at home. Sorting out the medicare part b vs part d biologics question before a treatment change is what separates a predictable cost from a surprise.

Route of administration decides the benefit category

Medicare Part B is the medical benefit. It pays for drugs given as part of a physician's service, and the regulation covering services and supplies furnished incident to a physician's service includes drugs and biologicals that are not usually self-administered. The companion rule sets the boundary explicitly: Part B excludes any drug or biological that is usually self-administered by the patient, with narrow exceptions for things like blood clotting factors and erythropoietin.

Part D, the outpatient prescription benefit, picks up what Part B leaves behind. The definition of a Part D drug specifically excludes drugs for which payment is available under Part A or Part B, even when the beneficiary has declined to enroll in those parts. The two benefits are designed not to overlap, so a given administration of a given drug lands in one bucket or the other.

For IBD that produces a clean split at the level of the product. Infliximab, sold as Remicade, is administered by intravenous infusion in a clinic or infusion center, which puts it on the medical side. Adalimumab, sold as Humira, is given at home by subcutaneous injection for both Crohn's disease and ulcerative colitis, which puts it on the pharmacy side.

What you actually pay under each part

The cost structures are built differently, and that is where the practical stakes sit. Under Part B, Medicare generally pays 80 percent of the approved amount and the beneficiary is responsible for the remaining 20 percent coinsurance after the annual deductible. That percentage has no ceiling of its own. On an expensive infused biologic given every eight weeks, 20 percent recurs at every visit for as long as treatment continues. Many beneficiaries close that gap with a Medicare supplemental policy, which is designed to pay expenses left unreimbursed by Medicare because of deductibles and coinsurance, or through retiree or employer secondary coverage.

Part D now works the opposite way. The Inflation Reduction Act replaced the old catastrophic coinsurance with a hard annual out-of-pocket threshold. The regulation sets that threshold at $2,000 for 2025, indexed in later years by the annual percentage increase in Part D drug expenditures and rounded to the nearest $50, and once an enrollee's incurred costs pass it, cost sharing for the rest of the calendar year is zero. A 2025 analysis of Medicare claims found the benefit varies enormously between beneficiaries, because many high spenders were already insulated by retiree drug coverage and never would have reached the cap. For someone with no supplemental drug coverage on a specialty IBD biologic, the cap is the most consequential change in years.

Two other Part D features matter for IBD patients on fixed incomes. The Medicare Prescription Payment Plan, which began in 2025 and lets beneficiaries repay out-of-pocket costs in interest-free monthly installments, smooths the annual total without lowering it. The low-income subsidy known as Extra Help sharply reduces Part D cost sharing for beneficiaries under income and resource limits, and it is automatic for people dually eligible for Medicare and Medicaid.

Drugs that sit on both sides of the line

Several modern IBD biologics complicate the picture because a single course of therapy uses two routes. Ustekinumab, sold as Stelara, starts with a single weight-based intravenous infusion and then moves to 90 mg subcutaneously every eight weeks. Risankizumab, sold as Skyrizi, uses intravenous induction at weeks 0, 4, and 8, then 180 mg or 360 mg subcutaneously from week 12 onward. Vedolizumab, sold as Entyvio, is available both as a lyophilized powder for intravenous infusion and as a subcutaneous pen, so the same molecule can be billed either way depending on which formulation is prescribed.

In each of these cases the induction doses typically fall under the medical benefit and the maintenance doses under the pharmacy benefit. The switch happens on a specific calendar date, often around week 8 or 12, and it can bring a new prior authorization, a new pharmacy, and a different cost calculation. One study of prior authorization in inflammatory bowel disease found biologic initiation delayed by a median of 10.2 days in standard cases and 24.6 days when appeals or step therapy were involved, and a separate study of dose escalation approvals reported a median of 7 days that stretched to 29 days when an appeal was required.

A call script for your plan

Call the number on the back of your Medicare Advantage or Part D card, or 1-800-MEDICARE for Original Medicare questions, and work through these questions in order. Write down the representative's name, the date, and any reference number.

• "I am starting [drug name]. Is this drug billed under my Part B medical benefit or my Part D drug benefit, and does that answer change between the induction doses and the maintenance doses?"
• "If it is Part B, what is my coinsurance per dose, does my supplemental policy pay it, and is the infusion site in network? If it is Part D, what tier is it on, what is my cost until I reach the annual out-of-pocket threshold, and which specialty pharmacy must fill it?"
• "Does this drug require prior authorization or step therapy under that benefit, how long does a decision take, and what does my prescriber need to submit?"

Ask the same questions again at every treatment change, including a switch from infusion to a self-injected form of the same drug, a dose escalation, a biosimilar substitution, and any January plan change. The historical pattern in Medicare reimbursement is that payment rules for infused and self-administered biologics evolve on separate tracks, so an answer that was correct last year may not be correct now.

Benefit category is a billing fact rather than a clinical one, but it drives what a patient pays, which pharmacy dispenses the drug, and how long approval takes. Because the answer depends on route of administration, formulation, and plan type at once, it cannot be inferred from the drug name alone. Confirming it before the first dose, and again whenever the regimen changes, keeps a coverage question from becoming an interruption in therapy.